DR. STANFORD MARK MORAN, M.D.
Osteopathic Medicine at Orinda View Rd, Orinda, CA
License number
California G046555
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G046555
Category
Osteopathic Medicine
Type
Nephrology
License number
California G046555
Category
Osteopathic Medicine
Type
Clinical Pharmacology
Address
Address
55 Orinda View Rd, Orinda, CA 94563
Phone
(510) 867-5876
(925) 317-3956 (Fax)
(925) 317-3956 (Fax)
Professional information
Methods Of Treating Proliferative Disorders
US Patent:
6566395, May 20, 2003
Filed:
May 22, 2000
Appl. No.:
09/577689
Inventors:
Stanford Mark Moran - Orinda CA
Assignee:
BioMedicines, Inc. - Alameda CA
International Classification:
A61K 31275
US Classification:
514521
Abstract:
Disclosed are methods and compositions for treating proliferative disorders, such as cancers, blood vessel disorders, fibrotic disorders and acute or chronic rejection of transplanted organs, tissue or cells, using compounds of formula I or a tautomeric isomer thereof: wherein R and R are as defined; or a pharmaceutically-acceptable salt or pro-drug thereof.
Method Of Diminishing The Adverse Effects Of Interleukin-2
US Patent:
2002001, Feb 7, 2002
Filed:
Aug 16, 2001
Appl. No.:
09/932011
Inventors:
Stanford Moran - Orinda CA, US
International Classification:
A61K031/352
US Classification:
514/456000
Abstract:
A method and composition for preserving or enhancing the beneficial effects of interlude-2 (IL-2) while simultaneously mitigating the adverse effects of IL-2 on a subject is disclosed. The method involves administering an amount of a leukotriene B(LTB) antagonist, preferably a LTBreceptor antagonistic, to a subject exhibiting adverse pharmacological effects due to exogenous IL-2, where the amount administered to the subject is sufficient to decrease the IL-2 induces adverse effects. Also disclosed is an article of manufacturing comprising a composition of the leukotriene Bantagonist in combination with labeling instructions for treatment. Also disclosed is a method for preparing a pharmaceutical composition. Generally the LTBantagonist will reduce the IL-2-induced adverse effects while preserving or enhancing the anti tumor, antiviral, or immunostimulatory effects of IL-2, thereby improving the therapeutic index of IL-2.
Combination Therapy For The Treatment Of Estrogen-Sensitive Disease
US Patent:
2005017, Aug 11, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982697
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
A61K031/56, A61K031/55, A61K031/445, A61K031/138
US Classification:
514171000, 514217040, 514319000, 514651000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.
Method For Short-Term And Long-Term Drug Dosimetry
US Patent:
2005019, Sep 1, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982398
Inventors:
Stanford Moran - Orinda CA, US
International Classification:
A61K038/21, A61K009/22
US Classification:
424085400, 604890100
Abstract:
Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.
Combination Therapy For The Treatment Of Estrogen-Sensitive Disease
US Patent:
2005013, Jun 16, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982533
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
A61K031/138, A61K031/56
US Classification:
514171000, 514651000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.
Method For Short-Term And Long-Term Drug Dosimetry
US Patent:
2002019, Dec 26, 2002
Filed:
Oct 30, 2001
Appl. No.:
10/004118
Inventors:
Stanford Moran - Orinda CA, US
International Classification:
A61K038/21
US Classification:
424/085500, 424/085600, 424/085700
Abstract:
Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.
Method For Short-Term And Long-Term Drug Dosimetry
US Patent:
2005020, Sep 15, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982532
Inventors:
Stanford Moran - Orinda CA, US
International Classification:
A61K038/21, A61K009/22
US Classification:
424085400, 604890100
Abstract:
Methods for the treatment of interferon-response disorders by administration of an interferon alone or in combination with adjunctive therapy are described. The invention encompasses providing to a patient both a formulation of an interferon that is suitable for short-term administration and a formulation of an interferon associated with a sustained release delivery system that is suitable for long-term administration. A principal advantage of the method is that responsiveness to treatment can be ascertained with short-term dosimetric techniques using one formulation of an interferon, which permits the appropriate selection of a dose that is both effective and safe for long-term administration using the second formulation.
Combination Therapy For The Treatment Of Estrogen-Sensitive Disease
US Patent:
2005022, Oct 13, 2005
Filed:
Jun 3, 2005
Appl. No.:
11/144915
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
C12Q001/00, A61K031/137
US Classification:
514651000, 435004000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.